Stromal Cells for GVHD Prevention

Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease After Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies and Myelodysplasia

More Information

Trial Status
Not currently accepting
Trial Phase
Phase 1
Enrollment
45 patients (estimated)
Sponsors
Ossium Health, Inc.
Collaborators
Winship Cancer Institute
Tags
Post-Allogeneic Stem Cell Transplant
Trial Type
Supportive
Last Update
3 months ago
SparkCures ID
1547
NCT Identifier
NCT04328714

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.